Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Liquid-based cytology

This article was originally published in The Gray Sheet

Executive Summary

Technology is recommended by NICE in 1LBC guidance as the primary means of processing Pap smear samples in the UK's cervical screening program. The UK body released a final appraisal on the procedure in August (2"The Gray Sheet" Aug. 18, 2003, In Brief)...

You may also be interested in...



NICE endorses liquid-based cytology

National Institute for Clinical Excellence final appraisal determination issued Aug. 15 recommends using the technology as the primary means of processing samples in the UK's cervical screening program. Implementation of the policy - representing 4 mil. annual tests - should take about three to five years. The decision was applauded by LBC stakeholders Cytyc (ThinPrep) and TriPath (SurePath). NICE issued a preliminary recommendation in April (1"The Gray Sheet" April 21, 2003, p. 6)...

Cosmetic And Personal Care Trademark Review 24 November, 2020

Personal care and cosmetic product trademark filings compiled from the Official Gazette of the US Patent and Trademark Office, Class 3.

CBD Health Benefits More Attractive To Women? FDA Prioritizes Research Into Utero Effects

Among the largest gaps in safety data is non-clinical research on CBD use's effect on developing fetus and adolescent brain, in utero/lactational exposure, reproductive toxicity and the potential for a latency period before toxicity, says FDA  neuroscientist Andrew Shen.

UsernamePublicRestriction

Register

LL1134531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel